The Post-Discontinuation Support Gap: An Opportunity for GLP-1 Prescribers
65% of patients stop GLP-1 treatment within a year, yet no competitor offers structured post-treatment support. Here's why that gap is your opportunity.
Key takeaways
- Up to 68% of GLP-1 patients discontinue within 12 months, yet every companion app and support service goes silent at that point.
- Patients who stop are not lost — 27% switch medications and many restart within a year. These are prescriptions flowing back to whoever maintained the relationship.
- No competitor in the UK market offers structured post-discontinuation support. This is clear whitespace.
- Post-discontinuation patient data (weight trajectories, appetite scores, quality of life) is the most commercially valuable and least available data in the GLP-1 lifecycle.
- NICE guidance already expects ongoing monitoring and behavioural support after treatment ends. Post-treatment support is not optional — it is what commissioners are looking for.
The cliff
Here is a number that should concern every GLP-1 prescriber: only 32% of patients persist on therapy at 12 months. At two years, that drops to 15%.
That is real-world data from Prime Therapeutics. Clinical trials show retention above 85% — the gap tells you something important about what happens when patients leave the controlled environment of a study.
The reasons patients stop are well documented: side effects in the first 90 days, cost pressure, weight loss plateaus around weeks 8 to 12, supply disruptions, and patients who reach their target weight and decide they are done.
What happens next is the problem. When a patient stops their GLP-1 medication, every digital tool, companion app, and support service they were using goes quiet. Injection reminders stop. Dose tracking becomes irrelevant. The weekly content dries up. The patient is left to manage the most physiologically challenging phase of their treatment journey entirely alone.
The commercial problem
Consider the economics. You invested in acquiring that patient — whether through marketing, NHS referral pathways, or word of mouth. You managed the consultation, the prescribing decision, the titration schedule. You supported them through early side effects, adjusted doses, answered questions between appointments. You built a clinical relationship over months.
Then they stop, and you lose them.
Not because they had a bad experience. Not because they found a better service. Simply because your support model, like everyone else’s, is built around active treatment. When the prescription ends, the relationship ends. The patient walks out the door and, statistically, many of them will restart treatment within a year — but often with a different provider, because nobody kept the connection alive.
The patient acquisition cost is sunk. The lifetime value is halved. And the clinical data you collected during their treatment is incomplete, because you have no visibility into what happened after they left.
What no one is building
We conducted a comprehensive scan of the UK and international GLP-1 support landscape. The finding was unambiguous: no competitor currently offers a dedicated, structured post-discontinuation programme.
The UK market includes Shotsy, Glapp, Voy, Noom, and Pep — all focused on supporting patients during active treatment. Injection tracking, dose reminders, side effect logging. Useful tools, but they assume the patient is on medication. Second Nature and Juniper bundle behavioural coaching with GLP-1 prescribing, but their revenue models depend on ongoing medication subscriptions. Building a post-discontinuation programme would cannibalise their core business. Roczen offers affordable community support but nothing structured for cessation.
The closest international comparator is Omada Health (US), whose published data shows 63% of members maintained weight 12 months after stopping GLP-1s. But Omada is US-only, employer-sold, and their post-discontinuation support is incidental rather than purpose-built.
Pharma has no incentive to fill this gap. Novo Nordisk’s STEP 1 extension trial showed two-thirds of weight loss regained within 12 months of stopping Wegovy. Lilly’s SURMOUNT-4 data argues for indefinite continuation. Both companies’ strategic interest is in reducing discontinuation, not supporting patients through it.
The result is a structural market gap. Every player in the GLP-1 ecosystem is focused on keeping patients on medication or supporting them while they are on it. Nobody is building for the moment they stop.
Why patients come back
The Cleveland Clinic published a study in March 2026 analysing approximately 8,000 patients who discontinued GLP-1 therapy. One finding stood out: 27% of patients who stopped switched to a different medication within 12 months. Many others restarted the same medication after a gap.
The pattern is predictable. A patient stops treatment. Over the following weeks, appetite returns to pre-treatment levels — the research shows this happens within two to four weeks as the drug clears. Weight begins to regain at roughly 0.4 kg per month. At some point — typically within six to twelve months — the patient crosses a personal threshold and seeks treatment again.
These are prescriptions waiting to happen. The question is whether they flow back to you or to whoever the patient finds when they go looking.
If you maintained a support relationship during the post-treatment period — even lightweight digital contact — you are the natural first call when the patient decides to restart. If you let the relationship lapse, you are competing for that patient all over again, against every online prescriber and pharmacy running Google Ads for “semaglutide UK.”
The restart pathway also has clinical implications. Patients who have been off semaglutide for more than 35 days, or tirzepatide for more than 25 days, require full re-titration from the starting dose. A structured post-treatment relationship means you can guide that process safely rather than the patient attempting to self-restart at their previous dose — a genuine safety risk.
The data opportunity
Post-discontinuation is where the most commercially valuable data in the GLP-1 lifecycle sits, and almost none of it is being collected.
Pharma companies urgently need real-world weight trajectory data after cessation. Clinical trials measure this, but with small sample sizes and highly selected populations. Real-world post-discontinuation data — weekly weight measurements, stratified by demographics, treatment duration, and discontinuation reason — is exactly what health economics and outcomes research teams need for NICE technology appraisals and HTA submissions.
Beyond weight, there is no published study tracking EQ-5D-5L quality of life scores across the discontinuation transition — the standard instrument for NICE health technology appraisals. Food preoccupation scores, mental health outcomes, comorbidity changes, time-to-restart patterns — all of this data is being lost because no one maintains the patient relationship long enough to collect it.
For prescribers, the implication is practical. If you continue to engage patients after treatment ends and collect structured outcome data with appropriate consent, you are building a dataset that has commercial value to pharmaceutical companies, NHS commissioning bodies, and academic researchers. That is not a theoretical future — it is a current, quantifiable gap in the evidence base.
NICE alignment
NICE TA1026 (tirzepatide for weight management) requires ongoing monitoring and behavioural support as part of the treatment pathway. CG189 (obesity management) recommends long-term follow-up after any weight management intervention. The NHS interim commissioning guidance for tirzepatide implementation emphasises integration with lifestyle services to “maximise results and prevent weight regain when treatment stops.”
The language is clear: prescribing a GLP-1 without a plan for what happens when it stops is not aligned with current commissioning expectations. The 2-year treatment limit on NHS-funded semaglutide (NICE TA875) guarantees a growing cohort of patients who will be discharged from specialist weight management with no structured post-treatment pathway.
For pharmacy owners and clinic directors positioning for NHS Weight Management Service tenders, post-discontinuation support is what commissioners expect to see in a credible service specification. Offering it demonstrates clinical governance. Not offering it is increasingly difficult to justify.
The pharmacy advantage
You dispensed the medication. You managed the titration. You saw the patient regularly throughout treatment. You understand their clinical history, their side effect profile, their response to dose changes. No online platform or pharma company has that relationship.
The question is not whether post-discontinuation support will become standard practice — the weight of evidence and commissioning guidance makes that inevitable. The question is whether you offer it proactively or wait until a competitor does.
A structured post-treatment programme changes the conversation at discontinuation. Instead of “your prescription has ended, good luck,” it becomes “your prescription has ended, and here is what the next year looks like.” That is the kind of differentiation that drives referrals, retention, and reputation.
What structured post-treatment support looks like
Effective post-discontinuation support is not simply extending the on-treatment programme. The clinical challenges are different, and the content must reflect that.
In the first four weeks after the final dose, support needs to be intensive — daily contact at minimum. This is when appetite returns, when the psychological impact of losing appetite suppression is highest, and when patients are most likely to feel abandoned by the healthcare system. Content should be adapted to the specific reason for discontinuation — a patient who stopped due to side effects has different needs from one who reached their target weight.
From weeks 5 through 24, the focus shifts to behavioural consolidation: resistance training, protein targets, self-monitoring, and managing the return of food preoccupation. This is also when most restart decisions are made, so the pathway should include safe guidance on returning to treatment — routed back to the same prescriber.
Throughout, structured data collection continues: weight, appetite scores, quality of life, comorbidity markers. Whether the patient maintains their weight loss, restarts treatment, or transitions to an alternative approach, they do so with clinical support and within a relationship that serves both their interests and yours.
Cadence Health is building structured post-discontinuation support as part of its GLP-1 patient platform. If you are interested in offering 104 weeks of total patient support — 52 weeks on treatment, 52 weeks after — get in touch at hello@cadencehealth.uk.
References: STEP 1 extension trial (Wilding et al., 2022); SURMOUNT-4 (Aronne et al., 2023); Cleveland Clinic real-world GLP-1 discontinuation study (March 2026); Prime Therapeutics GLP-1 persistence data (2025); Omada Health ANSWERS Initiative (2025, n=816); Oxford/BMJ systematic review of post-pharmacotherapy weight regain (January 2026); Penn Medicine brain activity study (Nature Medicine, November 2025); NICE TA1026, TA875, CG189; NHS England interim commissioning guidance for tirzepatide (March 2025); Washington University cardiovascular outcomes study (BMJ Medicine, March 2026).